Harvey I. Pass, MD

Articles by Harvey I. Pass, MD

Future Perioperative Strategies in Non-Small Cell Lung Cancer

ByCharu Aggarwal, MD, MPH,Benjamin P. Levy, MD,Harvey I. Pass, MD,Heather Wakelee, MD

May 27th 2022

Before closing out their discussion on non–small cell lung cancer, experts share excitement for possible improvements in the setting of perioperative therapy.

Targeted and IO Therapy in EGFR Exon 19 Deletion–Positive NSCLC

ByCharu Aggarwal, MD, MPH,Benjamin P. Levy, MD,Harvey I. Pass, MD,Heather Wakelee, MD

May 27th 2022

Experts consider when and if it would be appropriate to utilize targeted or immunotherapy in patients with EGFR exon 19 deletion–positive NSCLC.

Patient Profile 2: EGFR Exon 19 Deletion–Positive NSCLC

ByCharu Aggarwal, MD, MPH,Benjamin P. Levy, MD,Harvey I. Pass, MD,Heather Wakelee, MD

May 20th 2022

Shared insight on the diagnosis and management of EGFR exon 19 deletion–positive NSCLC, with regard for the potential of osimertinib in this setting.

NSCLC: Selecting Therapy Based on PD-L1 Status and Staging

ByCharu Aggarwal, MD, MPH,Benjamin P. Levy, MD,Harvey I. Pass, MD,Heather Wakelee, MD

May 20th 2022

A brief review of how treatment may be selected for a patient with NSCLC based on their PD-L1 expression and disease staging.

IMpower010 and KEYNOTE-091: Adjuvant Immunotherapy in NSCLC

ByCharu Aggarwal, MD, MPH,Benjamin P. Levy, MD,Harvey I. Pass, MD,Heather Wakelee, MD

May 13th 2022

Expert perspectives on the IMpower010 and KEYNOTE-091 trials, which assessed adjuvant immunotherapy in non–small cell lung cancer.

CheckMate-816: Neoadjuvant Chemoimmunotherapy for NSCLC

ByCharu Aggarwal, MD, MPH,Benjamin P. Levy, MD,Harvey I. Pass, MD,Heather Wakelee, MD

May 13th 2022

Shared insight on the CheckMate-816 trial and how immunotherapy may have a role in the neoadjuvant setting of non–small cell lung cancer.

Role of Immunotherapy in Newly Diagnosed NSCLC

ByCharu Aggarwal, MD, MPH,Benjamin P. Levy, MD,Harvey I. Pass, MD,Heather Wakelee, MD

May 6th 2022

A broad discussion on the role of immunotherapy in newly diagnosed NSCLC in both the neoadjuvant and adjuvant settings.

Patient Profile 1: Stage IIB NSCLC With High PD-L1 Expression

ByCharu Aggarwal, MD, MPH,Benjamin P. Levy, MD,Harvey I. Pass, MD,Heather Wakelee, MD

May 6th 2022

Shared insight on a patient profile of newly diagnosed non–small cell lung cancer with high PD-L1 expression and no driver mutation.

Factors in Selecting Therapy for Non-Small Cell Lung Cancer

ByCharu Aggarwal, MD, MPH,Benjamin P. Levy, MD,Harvey I. Pass, MD,Heather Wakelee, MD

April 29th 2022

Expert panelists look at all factors that inform treatment selection when managing a patient diagnosed with non–small cell lung cancer.

Biomarker Testing Practices in Non-Small Cell Lung Cancer

ByCharu Aggarwal, MD, MPH,Benjamin P. Levy, MD,Harvey I. Pass, MD,Heather Wakelee, MD

April 29th 2022

Comprehensive discussion on how biomarker testing and multidisciplinary care can improve the management of non–small cell lung cancer.

Controversies in the Treatment of Mesothelioma of the Pleura

ByHarvey I. Pass, MD

June 23rd 2011

In this exclusive video, Dr. Harvey Pass discusses surgery in mesothelioma of the pleura and other areas of disagreement.

Principles of Chemoradiation: Theoretical and Practical Considerations

ByLaurie L. Herscher, MD,John A. Cook, PhD,Angelo Russo, MD, PhD,James B. Mitchell, PhD,Roberto Pacelli, MD,Harvey I. Pass, MD

October 1st 1999

Chemotherapy agents known to enhance the effects of radiation in preclinical studies have been used concurrently with radiotherapy in numerous clinical trials with the prospect of further enhancing radiation-induced